skip to Main Content

Examination of Diabetes and Cholesterol Drugs in Pancreatic Cancer Mortality Shows Improved Survival with Use of One More Than the Other

Newsfeed image, light gray text on dark gray background
Research has shown that by themselves, the diabetes drug metformin and cholesterol-lowering drugs known as statins are associated with reduced cancer mortality, but little is known about the effect on pancreatic cancer mortality when these drugs are taken together.

Investigators at Rutgers Cancer Institute of New Jersey and other collaborators examined Surveillance, Epidemiology, and End Results (SEER) Medicare data to further explore this approach and found that exposure to statins for these patients was significantly associated with reduced overall mortality. Results of the work are being presented as part of a poster session at the American Association for Cancer Research Annual Meeting being held this week in Washington, D.C. Read more . . .

Back To Top